Is sildenafil appropriate for treating pulmonary hypertension caused by heart failure with reduced ejection fraction (HFrEF)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 21, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Sildenafil is NOT Recommended for Pulmonary Hypertension Due to HFrEF

Sildenafil should not be routinely used to treat pulmonary hypertension secondary to heart failure with reduced ejection fraction (HFrEF). The highest quality evidence demonstrates no benefit on clinically meaningful outcomes, and current guidelines explicitly recommend against its use in this population.

Why Sildenafil Fails in Group 2 PH (PH-LHD)

The 2017 ACC/AHA/HFSA guidelines provide a Class III recommendation (harm/no benefit) with Level B-R evidence stating that routine use of phosphodiesterase-5 inhibitors to increase activity or quality of life in patients with HFpEF is ineffective 1. While this specific recommendation addresses HFpEF, the underlying pathophysiology and evidence extends to HFrEF with secondary PH.

The RELAX trial, which randomized 216 patients with heart failure (EF ≥50%) to sildenafil versus placebo, showed no improvement in oxygen consumption or exercise tolerance 1, 2. This negative trial fundamentally changed practice recommendations.

The Critical Distinction: PAH vs PH-LHD

Sildenafil is FDA-approved and guideline-recommended only for pulmonary arterial hypertension (PAH, WHO Group 1), not for pulmonary hypertension due to left heart disease (PH-LHD, WHO Group 2) 3, 4. The 2014 CHEST guidelines clearly recommend sildenafil for treatment-naive PAH patients with WHO FC III symptoms to improve 6-minute walk distance (Grade 1C) and functional class 3. However, these recommendations explicitly apply to PAH, not secondary PH from heart failure.

The Pathophysiologic Problem

Vasodilation in the setting of left heart disease can precipitate pulmonary edema. When you reduce right ventricular afterload with sildenafil in a patient with elevated left-sided filling pressures, you increase blood flow into a noncompliant left heart that cannot accommodate the increased preload 5. This mechanism explains why drugs effective in PAH fail—or even harm—patients with PH-LHD.

The 2023 European guidelines on pulmonary hypertension emphasize that there is limited and conflicting evidence for PAH drugs in Group 2 PH, and vasodilatation may result in pulmonary edema 5.

What the Research Actually Shows

While some older, small studies suggested hemodynamic improvements with sildenafil in HFrEF 6, 7, the most recent and highest quality trial contradicts these findings:

The SilHF trial (2022) randomized 69 patients with HFrEF and echocardiographic evidence of PH (PASP ≥40 mmHg) to sildenafil (up to 40 mg TID) versus placebo 8. Results showed:

  • No improvement in symptoms, quality of life, PASP, or 6-minute walk distance
  • Numerically more serious adverse events in the sildenafil group (33% vs 21%)
  • The trial was stopped early due to futility

This represents the best available evidence specifically addressing your question, and it definitively shows no benefit.

The One Potential Exception: Severe Precapillary Component

The 2022 ESC/ERS guidelines suggest that in cases of severe precapillary component (PVR >5 Wood Units) in the context of combined pre- and postcapillary PH (CpcPH-LHD), an individualized approach to treatment should be evaluated 5. This represents a very narrow subset where sildenafil might be considered, but only:

  • After right heart catheterization confirms PVR >5 WU
  • In consultation with a pulmonary hypertension center
  • With close hemodynamic monitoring
  • After optimizing standard HFrEF therapy first

What You Should Do Instead

The primary therapeutic strategy in PH-LHD is optimal treatment of the underlying cardiac disease 5, 9. This means:

  1. Maximize guideline-directed medical therapy for HFrEF 10:

    • ACE inhibitors or ARNi (sacubitril/valsartan)
    • Beta-blockers
    • Mineralocorticoid receptor antagonists
    • SGLT2 inhibitors
  2. Optimize volume status with diuretics 5

  3. Consider newer agents that may reduce pulmonary pressures:

    • SGLT2 inhibitors, GLP-1 agonists, and ARNIs may reduce PAP in HFrEF 5
  4. Refer to a PH center if combined pre/postcapillary PH with PVR >5 WU for complete diagnostic workup 5

Common Pitfalls to Avoid

  • Do not extrapolate PAH data to PH-LHD: The pathophysiology is fundamentally different
  • Do not use echocardiographic estimates alone: If considering PAH-specific therapy, right heart catheterization is mandatory to confirm hemodynamics and exclude elevated PAWP
  • Do not assume "pulmonary hypertension" means sildenafil is appropriate: The WHO classification matters critically—Group 1 (PAH) responds; Group 2 (PH-LHD) does not

The 2016 ESC guidelines on heart failure notably do not recommend sildenafil or other PDE-5 inhibitors for HFrEF, and list no indication for their use in this population 10.

References

Guideline

what changed after the 2022 guidelines for pulmonary hypertension?

European journal of internal medicine, 2023

Research

Sildenafil in heart transplant candidates with pulmonary hypertension.

Archives of cardiovascular diseases, 2015

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.